<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00825123</url>
  </required_header>
  <id_info>
    <org_study_id>141/07 bayside health</org_study_id>
    <nct_id>NCT00825123</nct_id>
  </id_info>
  <brief_title>Effects of Heart Rate Reduction on Central Arterial Pressure in Healthy Individuals</brief_title>
  <official_title>The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayside Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baker Heart and Diabetes Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayside Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to determine the effects of slowing heart rate upon both&#xD;
      central and peripheral blood pressures using Ivabradine. The effects of Ivabradine will be&#xD;
      compared to Metoprolol and placebo.&#xD;
&#xD;
      Participants will attend the hospital for 3 visits where they will be randomised to receive&#xD;
      either Ivabradine, Metoprolol and placebo on each visit. Non-invasive measures of blood&#xD;
      pressure will be recorded before and after consuming the study drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will undergo three days of laboratory testing, each visit separated by at least&#xD;
      seven days.&#xD;
&#xD;
      In order to assess each potential participant's suitability for the study based upon the&#xD;
      relevant inclusion and exclusion criteria, the first visit will involve a medical&#xD;
      consultation (history and physical examination), venepuncture (for full blood examination,&#xD;
      lipid profile and biochemistry) and a 12-lead surface electrocardiogram. Baseline&#xD;
      measurements of central and peripheral arterial and pulse wave velocity will be made at&#xD;
      baseline, and 4 hours following the administration of either placebo, 50mg of metoprolol or a&#xD;
      10mg oral dose of ivabradine. The placebo will contain lactose powder.&#xD;
&#xD;
      Subjects will be randomized according to a 3-by-3 Latin square design. Central pulse pressure&#xD;
      will be assessed using carotid artery tonometry using a non-invasive Millar Mikro-tip&#xD;
      pressure transducer. The transducer is used to applanate the carotid artery and calibrated&#xD;
      using brachial mean and diastolic blood pressure (automated oscillometric sphygmomanometer).&#xD;
&#xD;
      Pressure waveforms will also be recorded at the radial, brachial and femoral arteries to&#xD;
      permit study of wave reflection at these sites.&#xD;
&#xD;
      Measurements will be taken be taken before and 4 hours following the oral administration of&#xD;
      metoprolol/ivabradine/placebo.&#xD;
&#xD;
      Bias will be minimized by blinding both the participants and research staff responsible for&#xD;
      data collection to the administered drug.&#xD;
&#xD;
      Any potential patient-specific confounding factors will have minimal impact, as the same&#xD;
      participants will be studied after the administration of the three agents.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 8, 2011</completion_date>
  <primary_completion_date type="Actual">November 8, 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>central arterial pressure</measure>
    <time_frame>baseline and 4 hours post treatment</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Central Arterial Pressure</condition>
  <arm_group>
    <arm_group_label>Ivabradine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>Ivabradine 10 mg once</description>
    <arm_group_label>Ivabradine</arm_group_label>
    <other_name>Coralan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>Metoprolol 50 mg once</description>
    <arm_group_label>Metoprolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lactose powder</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy volunteers:&#xD;
&#xD;
          -  aged 18 - 25 years OR&#xD;
&#xD;
          -  aged &gt;60 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic disease&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Treated or untreated systemic arterial hypertension (SBP &gt;160mmHg and/or DBP &gt; 90mmHg)&#xD;
&#xD;
          -  Resting bradycardia (heart rate &lt; 60 beats/minute)&#xD;
&#xD;
          -  Pregnancy or active lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bronwyn A Kingwell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baker IDI Hearte &amp; Diabetes Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>January 15, 2009</study_first_submitted>
  <study_first_submitted_qc>January 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2009</study_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy individuals</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

